SAB Biotherapeutics (NASDAQ:SABS) Releases Earnings Results, Misses Expectations By $0.05 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings results on Wednesday. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05), Zacks reports. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%.

SAB Biotherapeutics Stock Down 17.2 %

NASDAQ:SABS traded down $0.68 during trading hours on Thursday, hitting $3.27. The company had a trading volume of 112,123 shares, compared to its average volume of 138,942. SAB Biotherapeutics has a 1 year low of $2.16 and a 1 year high of $9.72. The company has a 50-day moving average of $2.89 and a 200 day moving average of $3.02. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SABS shares. Craig Hallum started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target on the stock. Oppenheimer restated an “outperform” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.